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Background/aim: As the number of case reports related to the new type of coronavirus (COVID-19) increases, knowledge of and
experience with the virus and its complications also increase. Pleural complications are one relevant issue. We aimed in this study to
analyze pleural complications, such as pneumothorax, pneumomediastinum, and empyema, in patients hospitalized with the diagnosis
of COVID-19 pneumonia.
Materials and methods: The files of patients who have pleural complications of COVID-19 pneumonia and were consulted about
thoracic surgery between March 2020 and December 2020 were retrospectively reviewed. The data of the patients were analyzed
according to age, sex, length of stay, treatment method for pleural complications, mortality, severity of COVID-19 pneumonia, tube
thoracostomy duration, and presence of a mechanical ventilator.
Results: A total of 31 patients fulfilling the inclusion criteria were included in the study. There were 11 female (35.5%) and 20 male
(65.5%) patients. The most common complication was pneumothorax in 20 patients (65%). The median duration of hospitalization
was 22 days and the mortality rate was 71%. Mortality was significantly higher in patients on mechanical ventilation (p = 0.04).
Conclusion: The mortality rate is very high in patients with pleural complications of COVID-19 pneumonia. Pneumothorax is a fatal
complication in critically ill patients with COVID-19 pneumonia.
Key words: Pneumothorax, pneumomediastinum, COVID-19, empyema, pandemic

1. Introduction
As the number of case reports related to the new type of
coronavirus (COVID-19) that emerged at the end of 2019
and caused the pandemic increases, the knowledge about
its clinical conditions and complications also increases.
Patients with COVID-19 pneumonia may experience a
wide range of clinical conditions, from being
asymptomatic to dying due to respiratory failure. COVID19 pneumonia may be complicated by some pleural
complications
such
as
pneumothorax
(PT),
pneumomediastinum (PM), pleural effusion and
empyema [1–4]. In the physiopathology of PM in COVID19 pneumonia, the Macklin effect, in which alveolar
ruptures form due to increased intrathoracic pressure
caused by coughing, resulting in free alveolar air moving
from the hilus to the mediastinum through the
bronchovascular sheaths are blamed [5]. PT can occur
spontaneously due to pneumonia, or it can be
barotraumatic with positive airway pressure in patients
on mechanical ventilators [6,7]. Empyema due to COVID19 pneumonia is very rare in the literature and is
explained by the secondary infection of the pleural
effusion occurring via the inflammatory effect [8]. Here,
we aimed to analyze the data of patients with pleural
complications of COVID-19 pneumonia, including PT, PM,
and pleural effusion, in this retrospective study.
2. Materials and methods
2.1. Patient selection
After approval by the Republic of Turkey Ministry of
Health Ethics Committee (2020-10-16T13_53_24), we
*Correspondence: mervesatir@hotmail.com
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retrospectively reviewed the files of patients with pleural
complication of COVID-19 pneumonia and who consulted
with the Department of Thoracic Surgery in our hospital
between March 2020 and December 2020. COVID-19
diagnoses were made via thorax computed tomography
(CT), swab polymerase chain reaction (PCR) tests, or
antigen-antibody tests. The patients whose follow-up
records were not available, whose pleural complications
were not confirmed radiologically, and whose
complications occurred for iatrogenic reasons, such as
central venous catheterization or thoracentesis, were not
included in this study. Analyses were performed
according to age, sex, length of stay, treatment methods
for complications, mortality, severity of COVID-19
pneumonia, duration of tube thoracostomy and the
presence of a mechanical ventilator.
2.2. Statistical analysis
Analyses were made using the SPSS (IBM, version 20, NY,
USA) program. Descriptive data were given as mean ±
standard deviation, median (minimum-maximum) or
number and frequency. The chi-squared test was used for
categorical variables and the log rank test was used for
continuous variables. Distribution normalization was
evaluated by histogram. Mean values were used for
normal distribution and median values were used for
asymmetrical distribution. Overall survival was
investigated using the Kaplan–Meier method and survival
differences between groups were investigated using the
log-rank and Cox-regression methods. Studies were
conducted at a 95% confidence interval; p <0.05 was
considered significant.
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3. Results
A total of 31 patients who met inclusion criteria were
included in the study. There were 11 female (35.5%) and
20 male (65.5%) patients. The characteristics of the
patients are given in Table. The median age was 67 (range:
31–90). The most common pleural complication was PT in
20 patients (64.5%) followed by isolated PM in 7 patients
(22.5%) and pleural effusion in 4 patients (Figures 1a–1c).
Pleural complications occurred in right side in 13 patients,
left side in 9 patients, and bilaterally in 2 patients (Figure
1d). The number of patients who need the mechanical
ventilators was 22 (3 of them with noninvasive
mechanical ventilator). Tube thoracostomy was
performed in 20 patients (2 of them bilaterally). The
treatment of 8 (40%) patients with pneumothorax was
completed successfully and their tube thoracostomies
were removed. The median hospitalization time was 22
days (range: 1–64) and the median duration of tube
thoracostomy was 9 (0–38) days. A total of 22 (71%)
patients died. During the 60-day follow-up, the mean
survival of patients with pleural complications was 31.3
days (SD: 3.6, Figure 2). The mean survival day was
significantly better in nonintubated patients than in
intubated patients (43 versus 27 days, respectively, p =
0.04, Figure 3). There were no significant correlations
between survival, and age (p = 0.7), etiology (p = 0.09),
and being older than 70 years (p = 0.2). Sixteen of (80%)
of 20 patients with pneumothorax needed mechanical
ventilation. Surgical treatments such as bullae excision,
primary repair, or pulmonary resection were not
performed for pneumothorax in any of the patients due to
their very poor general medical condition or the adequacy
of tube thoracostomy treatment. The most common
comorbidity of our series was hypertension in 12 (38.7%)
patients, followed by malignancy in 8 (25.8%) patients.
Other comorbidities were given in Table. Mortality
occurred in 3 of 6 patients who had no comorbidity and
20 of 25 patients with comorbidity. The mean survival
time in comorbidity-positive and -negative group were 18
and 29 days, respectively, but survival differences was not
statistically significant (p = 0.1). Our series included one
empyema case. The staphylococcus aureus strains were
isolated in the pleural fluid culture and she was treated
with tube thoracostomy, intrapleural lavage, and
intravenous antibiotics for 31 days. The patient was
discharged without surgical intervention.
4. Discussion
In this study, pleural complications occurring due to
COVID-19
pneumonia
were
analyzed.
Pleural
complications occurring in COVID-19 pneumonia cases
increase mortality, morbidity, interventional procedures
and patient costs. PM occurs via the Macklin effect, as
explained above. Due to the continuity of the mediastinal
and neck fascia, free air can move to the subcutaneous
area or peripheral to the subpleural region, causing PMsubcutaneous emphysema and PT, respectively [9].
Sometimes the coexistence of these three entities can be

Table. Characteristics of patients.
n

%

F

11

35.5

M

20

65.5

PT

17

54.8

PM

7

22.6

PT + PM

3

9.7

PE

3

9.7

Empyema

1

3.2

Spontaneous

19

61.3

NIMV

3

9.7

IMV

9

29

Exitus

22

71

Alive

9

29

Conservative

10

32.2

TT

21

67.8

Right

13

54.2

Left

9

37.5

Bilaterally

2

8.3

Bronchial asthma

3

9.6

COPD

4

12.9

Hypertension

12

38.7

DM

1

3.2

Malignancy

8

25.8

CAD

5

16.1

CVD

3

9.6

CRF

1

3.2

Cirrhosis

1

3.2

None

6

19.3

Age, Med., Range: 67 years (30–90 years)
Duration of H, Med, Range (Days): 2 (1–64)
Duration of TT, Med, Range (Days): 9 (1–38)
Sex

Pleural complications

MV

Mortality

Treatment

Side of PT, PE

Comorbidities

Abbreviations: CAD: coronary artery disease; COPD: chronic
obstructive pulmonary disease; CRF: chronic renal failure;
CVD: cerebro-vascular disease; DM: diabetes mellitus; F:
female, IMV: invasive mechanical ventilation, H:
hospitalization, M: male; Med: median; MV: mechanical
ventilation; NIMV: noninvasive mechanical ventilation; PE:
pleural effusion;
PM: pneumomediastinum; PT: pneumothorax, TT: tube
thoracostomy.
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Figure 1. a) Thorax CT shows left-sided pneumothorax in a patient with COVID-19 pneumonia; b) Coexistence of pneumomediastinum
and diffuse ground glass opacities are seen in tomography scan; c) Tomographic view of right-sided pleural effusion and mild COVID19 pneumonia; d) Thorax CT scan shows pneumomediastinum and bilateral pneumothorax.

detected. In our study, there were isolated PT in 17
patients, isolated PM in 7 patients, and coexistence of PMPT and subcutaneous emphysema in 3 patients. Mallick et
al. claimed that pleural complications in COVID-19
pneumonia occurred due to parenchymal degeneration as
a result of prolonged disease and severe inflammation [2].
Similarly, Oye et al. reported that the PM and PT in COVID19 pneumonia emerged due to damaging the lung
parenchyma with ischemic and inflammatory effects.
They also reported that the risk of complications was
increased with the severity of the disease [10].
Additionally, there are studies in the literature reporting
that PT is related to positive air pressure [11,12].
Hameed et al. concluded in their series including 3
patients that tube thoracostomy was required for 2
patients and the mean duration of the tube thoracostomy
was 11 days [13]. The median tube thoracostomy duration
was 9 days in our study. Udi et al. indicated in their study
including patients with respiratory failure requiring
mechanical ventilators that barotrauma was significantly
higher in the COVID-19 pneumonia group compared to
other, and they explained that this was due to the excess
parenchymal restriction [6]. In our study, the spontaneous
PT-PM/barotraumatic PT-PM ratio was 0.25 and it
2824

supported the inference by Udi et al.. Through the
literature review, we have seen that the severity of
pneumonia is excessive in patients who had pleural
complications of COVID-19 pneumonia [10,11,14]. In our
series, 80% of the patients had severe pneumonia in
accordance with the literature.
In general, there is no specific treatment for isolated
PM, and treatment is based on symptoms. If severe
mediastinal emphysema and subcutaneous emphysema
are present, free air can be drained [15]. In our study,
patients who developed isolated PM were followed up
with daily chest X-ray and the mediastinal emphysema
resolved in the following days spontaneously. It has been
reported that the mortality of pleural complication
occurring in COVID-19 pneumonia is quite high. It is not
clear whether this is related to the severity of the
underlying pneumonia or whether pleural complications
contribute to mortality. Mortality rate in our study was
over 70% and only 9 patients (29%) were discharged
successfully. Cases of effusion/empyema developing after
COVID-19 pneumonia are rarely reported in the literature.
Tessitore et al. published a case series including 3 patients
with empyema treated with surgical decortication. They
reported that a strong inflammatory response and added
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Figure 2. Overall survival of patients in the time of hospitalization.

Figure 3. There was a statistically significant survival difference between intubated and nonintubated patients (p = 0.04).

vasculitis and microvascular thrombosis in response to
infection in the lower respiratory tract caused reactive
pleural effusion and empyema developed with bacterial
superinfection [8]. On the other hand, Yarlagadda et al.
reported that empyema occurred via aspiration
pneumonia in their case report [4]. In our study, there

were 3 pleural effusion and 1 empyema cases. We thought
that the etiology was bacterial superinfection of the
reactive fluid in our patient who had a long duration of
hospitalization and had some comorbidities, such as
hemodialysis for renal failure, diabetes, and hypertension.
The patient was discharged without surgical intervention.
2825
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The limitations of our study were as follows; it is a
retrospective and single-centered study and included
small number cases. In addition, we could not make a
comparison with patient groups who did not have any
pleural complication of COVID-19 pneumonia or those
who were hospitalized for other viral pneumonia because
only patients who were consulted with our department
were included in the study. Another limitation of our
study was that we wanted to investigate the relationship
between inflammation parameters and survival.
However, these parameters were high in almost all of the
patients included the study since our study group was on
the hospitalized patients with COVID-19 pneumonia. In
addition, we did not decide on which blood value was
taken on which day of hospitalization. Additionally, the
number of patients included in our study was insufficient
for any analysis which determines cut-off value for
inflammation markers such as receiver operating
characteristics (ROC) analysis.
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